Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16657271 | 0.84 | MEN1 (0.52) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL19557713 | 0.82 | MEN1 (0.50) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL6934720 | 0.82 | AOC3 (0.37) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL18353018 | 0.80 | CYP3A4 (0.52) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL11093928 | 0.79 | MAPT (0.46) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL18352947 | 0.79 | ALDH1A1 (0.38) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL19900554 | 0.77 | MEN1 (0.62) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL1567556 | 0.77 | KMT2A (0.50) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL398169 | 0.76 | MAPT (0.54) | KMT2AMAPTMEN1NPSR1APOBEC3G | |
| SCHEMBL29549836 | 0.76 | MAPT (0.54) | KMT2AMAPTMEN1NPSR1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109956960-B | Synthetic method of isothiourea catalyst | 上海工程技术大学 | 2021-06-25 | — | — | CN | claimed |
| CN-109956960-B | Synthetic method of isothiourea catalyst | 上海工程技术大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-109956960-B | Synthetic method of isothiourea catalyst | 上海工程技术大学 | 2021-06-25 | — | — | CN | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-6806378-B2 | CATALYST SYSTEM AND A PROCESS FOR THE PREPARATION OF A NONRACEMIC CHIRAL ALCOHOL BY HYDROGENATION OF A KETONE USING THE CATALYST SYSTEM, WHEREIN THE CATALYST SYSTEM COMPRISES RUTHENIUM, A NONRACEMIC CHIRAL DIPHOSPHINE LIGAND, AN | DSM N.V. (NL) | 2004-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | KMT2A 2489/4885MAPT 592/4885MEN1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.